Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes-Reference-Cited by-同舟云学术

Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes

Published:2018-08 Issue:4 Volume:5 Page:642-648
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Mustroph Julian¹,Wagemann Olivia¹,Lücht Charlotte M.¹,Trum Maximilian¹,Hammer Karin P.¹,Sag Can Martin¹,Lebek Simon¹,Tarnowski Daniel¹,Reinders Jörg²,Perbellini Filippo³,Terracciano Cesare³,Schmid Christof⁴,Schopka Simon⁴,Hilker Michael⁴,Zausig York⁵,Pabel Steffen¹,Sossalla Samuel T.¹⁶,Schweda Frank⁷,Maier Lars S.¹,Wagner Stefan¹

Affiliation:

1. Department of Internal Medicine II; University Medical Center Regensburg; Franz-Josef-Strauß-Allee 11 93053 Regensburg Germany

2. Leibniz Research Centre for Working Environment and Human Factors; University of Dortmund; Dortmund Germany

3. Laboratory of Myocardial Electrophysiology, Imperial Centre for Translational and Experimental Medicine; Imperial College London; London UK

4. Department of Cardiothoracic Surgery; University Medical Center Regensburg; Franz-Josef-Strauß-Allee 11 93053 Regensburg Germany

5. Department of Anesthesiology; University Medical Center Regensburg; Franz-Josef-Strauß-Allee 11 93053 Regensburg Germany

6. Clinic for Cardiology and Pneumology; University Medical Center Göttingen; Göttingen Germany

7. Department of Physiology; University of Regensburg; Regensburg Germany

Funder

Marga und Walter Boll-Stiftung

Universität Regensburg

Deutsche Forschungsgemeinschaft

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ehf2.12336/fullpdf

Reference14 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

2. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial;Fitchett;Eur Heart J,2016

3. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial;Inzucchi;Diabetes Care,2018

4. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease;Wanner;Circulation,2018

5. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure;Byrne;JACC Basic Transl Sci,2017

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies;Chemico-Biological Interactions;2024-11

2. Effectiveness of sodium-glucose co-transporter 2 inhibitors on atrial fibrillation recurrence after catheter ablation: A systemic review and meta-analysis;International Journal of Cardiology;2024-10

3. The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review;Journal of Clinical Medicine;2024-09-12

4. Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms;Journal of Molecular and Cellular Cardiology;2024-09

5. Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions;American Journal of Physiology-Cell Physiology;2024-09-01